These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 15176157)

  • 1. New insights into imiquimod's mechanisms of action.
    Martín-García RF
    J Drugs Dermatol; 2004; 3(3):247-9. PubMed ID: 15176157
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [New perspective in immunotherapy: local imiquimod treatment].
    Kemény L; Nagy N
    Orv Hetil; 2010 May; 151(19):774-83. PubMed ID: 20427260
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhanced type I interferon signaling and recruitment of chemokine receptor CXCR3-expressing lymphocytes into the skin following treatment with the TLR7-agonist imiquimod.
    Wenzel J; Uerlich M; Haller O; Bieber T; Tueting T
    J Cutan Pathol; 2005 Apr; 32(4):257-62. PubMed ID: 15769273
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disease-independent skin recruitment and activation of plasmacytoid predendritic cells following imiquimod treatment.
    Urosevic M; Dummer R; Conrad C; Beyeler M; Laine E; Burg G; Gilliet M
    J Natl Cancer Inst; 2005 Aug; 97(15):1143-53. PubMed ID: 16077073
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of topical therapies in the management of cutaneous disease.
    Skinner R
    J Cutan Med Surg; 2004; 8 Suppl 3():22-31. PubMed ID: 15647859
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of topical immune response modifiers in skin cancer.
    Woodmansee C; Pillow J; Skinner RB
    Drugs; 2006; 66(13):1657-64. PubMed ID: 16978032
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Imiquimod treatment induces expression of opioid growth factor receptor: a novel tumor antigen induced by interferon-alpha?
    Urosevic M; Oberholzer PA; Maier T; Hafner J; Laine E; Slade H; Benninghoff B; Burg G; Dummer R
    Clin Cancer Res; 2004 Aug; 10(15):4959-70. PubMed ID: 15297396
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene expression in actinic keratoses: pharmacological modulation by imiquimod.
    Lysa B; Tartler U; Wolf R; Arenberger P; Benninghoff B; Ruzicka T; Hengge UR; Walz M
    Br J Dermatol; 2004 Dec; 151(6):1150-9. PubMed ID: 15606509
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical remission of classic Kaposi sarcoma with topical 5% imiquimod].
    Echeverría-García B; Sanmartín O; Guillén C
    Actas Dermosifiliogr; 2010 Mar; 101(2):181-2. PubMed ID: 20223165
    [No Abstract]   [Full Text] [Related]  

  • 10. Topical immunomodulation in dermatology: potential of toll-like receptor agonists.
    Hengge UR; Ruzicka T
    Dermatol Surg; 2004 Aug; 30(8):1101-12. PubMed ID: 15274700
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Topical imiquimod: mechanism of action and clinical applications.
    Vidal D
    Mini Rev Med Chem; 2006 May; 6(5):499-503. PubMed ID: 16719822
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The use of Toll-like receptor-7 agonist in the treatment of basal cell carcinoma: an overview.
    Stockfleth E; Trefzer U; Garcia-Bartels C; Wegner T; Schmook T; Sterry W
    Br J Dermatol; 2003 Nov; 149 Suppl 66():53-6. PubMed ID: 14616352
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Imiquimod - Its role in the treatment of cutaneous malignancies.
    Bubna AK
    Indian J Pharmacol; 2015; 47(4):354-9. PubMed ID: 26288465
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunomodulatory and pharmacologic properties of imiquimod.
    Sauder DN
    J Am Acad Dermatol; 2000 Jul; 43(1 Pt 2):S6-11. PubMed ID: 10861101
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Innovative uses of imiquimod.
    Vender RB; Goldberg O
    J Drugs Dermatol; 2005; 4(1):58-63. PubMed ID: 15696986
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Death receptor-independent apoptosis in malignant melanoma induced by the small-molecule immune response modifier imiquimod.
    Schön MP; Wienrich BG; Drewniok C; Bong AB; Eberle J; Geilen CC; Gollnick H; Schön M
    J Invest Dermatol; 2004 May; 122(5):1266-76. PubMed ID: 15140231
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Imiquimod as an antiangiogenic agent.
    Li VW; Li WW; Talcott KE; Zhai AW
    J Drugs Dermatol; 2005; 4(6):708-17. PubMed ID: 16302556
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune modulation and apoptosis induction: two sides of the antitumoral activity of imiquimod.
    Schön MP; Schön M
    Apoptosis; 2004 May; 9(3):291-8. PubMed ID: 15258460
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imiquimod as an immune response modulator in infectious conditions.
    Skinner RB
    Postgrad Med; 2002 Dec; 112(6 Suppl Using):8-16. PubMed ID: 19667608
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Imiquimod applied topically: a novel immune response modifier and new class of drug.
    Miller RL; Gerster JF; Owens ML; Slade HB; Tomai MA
    Int J Immunopharmacol; 1999 Jan; 21(1):1-14. PubMed ID: 10411278
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.